| Document |
Document Title |
|
WO/1994/008995A1 |
Compounds of formula (I), wherein formula (I) consists of formulae (I-1) to (I-4), and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, (I-1), (I-2), (I-3)...
|
|
WO/1994/007884A1 |
The invention aims at providing a safe technique for remarkably improving the yield of an alpha,beta-unsaturated ketone through introduction of an omega-chain into an aldehyde without being accompanied by the generation of hydrogen in th...
|
|
WO/1994/004161A1 |
The activity of inhibitors of vacuolar-type H+-ATPases in the inhibition of vacuolation induced by Helicobacter pylori is disclosed. Preferred agents are the macrolide antibiotics bafilomycins A1, A2, B1, B2, C1, C2 and D, especially baf...
|
|
WO/1994/004489A1 |
Cyclohexenonoxime ethers have formula (I) in which the substituents have the following meaning: R1 stands for alkyl; R2 for alkyl, halogen alkyl, alkenyl, halogen alkenyl, alkinyl or halogen alkinyl; -A1-O-N=CH-Ph or A2-W, in which A1 st...
|
|
WO/1994/001100A1 |
Disclosed is a novel class of antiandrogenic compounds including saturated and unsaturated fatty acids, their derivatives, and synthetic analogs, their method of synthesis, and their use in treating disorders associated with androgenic a...
|
|
WO/1993/018652A1 |
Inhibition of renal cancer, melanoma, colon cancer, lung cancer and leukemia cells by administration of compounds from the bafilomycin and hygrolidin groups of compounds.
|
|
WO/1993/018653A1 |
Inhibition of renal cancer, melanoma, colon cancer, lung cancer and leukemia cells by administration of compounds from the bafilomycin and hygrolidin groups of compounds.
|
|
WO/1993/015066A1 |
Benzopyran and other benzo-fused leukotriene B¿4? antagonists have formula (I) wherein A, n, R?1¿, R?2¿ and R?3¿ are as defined herein. The compounds of formula (I) wherein R?1¿ is c-substituted CR?4¿R?5¿-COOR?13¿ may be prepared...
|
|
WO/1993/015081A1 |
A morphinan derivative represented by general formula (1) or a pharmacologically acceptable acid addition salt thereof, an analgesic and diuretic containing the same as the active ingredient, and a process for producing the same. The inv...
|
|
WO/1993/015067A1 |
Benzopyran and other benzo-fused leukotriene B4 antagonists have formula (I) wherein R1 is a phenyl or substituted phenyl group, and A, n, R2 and R3 are as defined herein.
|
|
WO/1993/010107A1 |
Phenol derivatives are described as agonists of a cyclic AMP dependent protein kinase useful as medicaments.
|
|
WO/1993/009777A1 |
The present invention relates to novel tocotrienols and tocotrienol-like compounds displaying biological activity. The tocotrienols and tocotrienol-like compounds of this invention may be conveniently obtained from biological sources or ...
|
|
WO/1993/008800A1 |
A method for activating potassium channels and for treating hypertension, addiction, asthma, incontinence, and other conditions treatable by potassium channel activators, comprising administering a compound having formula (I), wherein R ...
|
|
WO/1993/009126A1 |
New A83543 components and salts thereof, and N-demethyl derivatives are useful for the control of insects and mites. Methods for making the new A83543 components by culture of $i(Saccharopolyspora spinosa) NRRL 18719, NRRL 18720, NRRL 18...
|
|
WO/1993/007128A1 |
This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral...
|
|
WO/1993/003372A1 |
Immunoassay methods and reagents for the quantification of total doxepins (i.e., E-doxepin, Z-doxepin, E-desmethyldoxepin, and Z-desmethyldoxepin) in a test sample are disclosed. The quantification of total doxepins is accomplished in an...
|
|
WO/1992/017440A1 |
Tricyclic compounds represented by general formula (I), pharmacologically acceptable salts thereof, and a process for producing the same. In formula (I) X represents -CH=CH-, -CH�2?O- or -O-; R?1� represents lower alkyl; R?2� repre...
|
|
WO/1992/015573A1 |
The practicality of known depolymerization reactions in which there is a danger of building up adherent residues on heat transfer surfaces is greatly improved by performing the process under conditions that provide a driving force which ...
|
|
WO/1992/013848A1 |
Certain novel hydroxamic acid and hydroxyurea derivatives having structure (I), wherein R1 is hydrogen, alkyl, alkenyl, amino or substituted amino, R4 is hydrogen, a pharmaceutically acceptable cation, aroyl or alkoyl, A is alkylene or a...
|
|
WO/1992/012133A2 |
Compounds of formula (I), wherein Q, X, R?1�, R?2�, R?9� and Z are as defined in the text, including compositions containing said compounds and a method for using them to control arthropods.
|
|
WO/1992/009284A1 |
Novel compounds which are 2,6-methano-2H-1-benzoxocincarboxamides having 5-HT3-antagonist properties including unique CNS, anti-emetic and gastric prokinetic activities and which are void of any significant D2 receptor binding affinity, ...
|
|
WO/1992/006061A1 |
An iridoide derivative synthesized from genipin, an aglycon of geniposide, which is useful as an antihyperlipemic agent and chologogue.
|
|
WO/1991/006296A1 |
A method for the treatment of diseases related to loss of bone mass such as osteoporosis, Paget's disease of bone, hyperparathyroidism, malignant neoplasms causing hypercalcinemia, parodontal diseases and implant-related bone loss compri...
|
|
WO/1990/015599A1 |
Use of compounds of formula (I) wherein A represents a group selected from (II) or (III), X represents -CH- or -N-; R1 represents a hydrogen or halogen atom, a C1-4 alkoxy group, a C1-4 alkyl group, or a C1-4 alkyl group substituted by 1...
|
|
WO/1990/015056A1 |
Novel compounds are provided of formula (I), or a pharmaceutically acceptable salt, ester or amide thereof, wherein A is O, S, CHR2, CR2 or C when n is 0 and A and R6 taken together form a nitrogen-containing 5-, 6- or 7-membered ring, a...
|
|
WO/1990/009790A1 |
The invention describes the use of macrolactones such as cladospolides and patulolides as drugs for the treatment of inflammatory allergies.
|
|
WO/1990/008763A1 |
The invention concerns novel, pharmaceutically useful, bensheterocyclyl sulphones of formula (I), in which ring A may bear optional halogeno, (1-4C)alkyl or fluoro(1-4C)alkyl substituents; X is oxygen, or a group of the formula -S(O)n- o...
|
|
WO/1990/007494A1 |
This invention relates to a new hydroxylamine derivative exhibiting a 5-lipoxygenase inhibitory activity and represented by general formula (I) (wherein R1 stands for aryl, aryloxy, arylthio, aryl(lower)alkyl, or aryl(lower)alkoxy, R2 fo...
|
|
WO/1990/006296A1 |
A liquid phase process for making perfluorinated organic substances which comprises directly contacting in a temperature-controlled reactor a diluted solution or dispersion of a perfluorinateable, organic substance in a liquid, inert med...
|
|
WO/1990/003373A1 |
The invention provides dibenz[b,e]oxepin derivatives represented by general formula (I), wherein R1 and R2 each represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, one of R3 and R4 is a group represent...
|
|
WO/1990/003399A1 |
Compounds and methods for the treatment and diagnosis of cancer are provided. Also provided are methods for isolating human amino acid transporters or subunits thereof, and substantially purified transporters or subunits. In particular, ...
|
|
WO/1989/012443A1 |
A compound of formula (I) and pharmaceutically acceptable acid addition salts thereof having antihistaminic activity wherein the various substituents are defined in the specification.
|
|
WO/1989/011477A1 |
A compound of formula (I) or, where appropriate, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof wherein: A represents >C=X or a bond; X represents O or S; Y represents N or N+-O- or a moiety ...
|
|
WO/1989/009770A1 |
A pentaene macrolide composition, referred to as faeriefungin, and compounds contained therein is described. The composition is produced by Streptomyces griseus var. Autotrophicus var. nov. The composition is useful for inhibiting the gr...
|
|
WO/1989/008130A1 |
Methods and materials are described for the preparation of novel immobilized membrane compositions. The described compositions are useful for evaluating membrane association characteristics of chemical compounds, and as a chromatographic...
|
|
WO/1989/003681A1 |
A racemic or optically active compound having the structural formula (I), wherein n is 0 or 1; X is CH2, O, S, SO, SO2, NH or N(C1-C4)alkyl; X1 is CH2, O, S, SO or SO2; Y and Y1 are taken together and form a carbonyl group, or Y and Y1 a...
|
|
WO/1989/003212A1 |
Variously substituted 3,5-dihydroxy-6,8-nonadienoic acids and esters, are blood cholesterol lowering agents and so are useful in the prevention and treatment of cardiovascular diseases such as atherosclerosis.
|
|
WO/1988/008836A2 |
Certain aryl substituted naphthalene, benzoxepine, benzazepine and benzocycloheptene derivatives are disclosed. The compounds are useful in treating hyperproliferative skin disease, allergic reactions and inflammation.
|
|
WO/1988/007530A1 |
Substituted imides of formula (I), are antipsychotic, anxiolytic agents with very little extrapyramidal side effects; in which X is -O-, -S-, -SO-, -SO2-, CR3R4- where R3 and R4, independently, are hydrogen, alkyl of 1 to 4 carbon atoms ...
|
|
WO/1988/007529A1 |
Substituted imides of formula (I) are antipsychotic, anxiolytic agents with very little extrapyramidal side effets, in which X is -O-, -S-, -SO-, -SO2- ,-CR3R4- where R3 and R4 independently, are hydrogen, alkyl of 1 to 4 carbon atoms or...
|
|
WO/1987/007894A1 |
Compound represented by general formula (I), (wherein R1 is H or methoxy, R2 is H, methoxy, OH or F, R3 is H or F, R4 is H or F attached to the 7-, 8- or 9- position, and Ar is benzene, thiophene or pyridine ring, provided that (i) at le...
|
|
WO/1987/005014A1 |
Compounds represented by general formula (I), (wherein Y-Z represents (II), -CH=CH- or -CH2CH2-, R1 and R2 each represents a substituent, R3 represents hydrogen, alkyl or alkoxy, R4 represents hydrogen, alkyl, optionally substituted alke...
|
|
WO/1986/001203A1 |
Compounds represented by general formula (I) (wherein A represents alkylene, Y-Z represents formula (II), -CH=CH-, -CH2CH2- or formula (III), R1 and R2 each represents a substituent, R3 represents hydrogen, alkyl or alkoxy, R4 represents...
|
|
WO/1986/000805A1 |
A new application of N-methyl-N- AD2-(6,11)-dihydrodibenz ADb,e BDoxepin-11-yl)ethyl BD-1-amino-3-phenoxy-propanol-(2) (Doxaminol) and compatible salts thereof for influencing the rheological properties of the blood, and pharmaceuticals ...
|
|
WO/1985/005621A1 |
Components of primysin antibiotic complex and the salts thereof and the process for the separation of the individual components by chromatography. A further object of the invention is a synergistic antimicrobial composition containing th...
|
|
WO/1984/004090A1 |
New tetra-alkyl-2, 2, 5, 5 cyclohexanone-4 ol-1 and their sulfonated derivatives of the general formula (I), wherein R and R', which may be the same or different, represent an alkyl radical (1-5 atoms of carbon) and R" represents a hydro...
|
|
WO/1982/001650A1 |
Novel heterobicyclic compounds of Formula I, processes for preparing same and pesticidal compositions and methods are described.
|
|
JP2024513500A |
As used herein, formula (I): [In the formula, variables (e.g., R1,R2,X1,X2,Y1,Y2,Y3,Y4,Y5,Y6,Y7, and Y8) values are as disclosed herein] or a pharmaceutically acceptable salt thereof. Also included herein are pharmaceutical compositions ...
|
|
JP2024026659A |
[Problem] The purpose is to design and synthesize a novel positively charged NSAIA prodrug that can be administered transdermally. Novel positively charged NSAIA prodrugs with chemical structures 1, 2a, 2b, 2c, or 2d were designed and sy...
|
|
JP7424115B2 |
An object of the present invention is to provide an industrially advantageous process for producing a t-butyl ester of 11-oxo-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, which is an intermediate for the production of olopatadine. The t-...
|
